New Frontiers in the Medical Therapy of Hepatocellular Carcinoma
Background: Hepatocellular carcinoma (HCC) is the most common primary liver tumor, and it rates fourth as a cause of cancer-related death. The presence of underlying liver disease and poor chemosensitivity pose major treatment challenges in the management of HCC. However, in the last few years the therapeutic scenario has substantially changed, and immunotherapy in the form of immune checkpoint inhibitors (ICPIs) has become an essential therapeutic strategy in this field.
Summary: After controversial results of monotherapy, ICPIs have been mainly investigated in association with anti-angiogenic agents or as dual checkpoin...
Source: Chemotherapy - January 9, 2022 Category: Cancer & Oncology Source Type: research
KIT Exon 9-Mutated Gastrointestinal Stromal Tumours: Biology and Treatment
Background. The majority of gastroinstestinal stromal tumours (GISTs) harbour oncogenic mutations in the gene encoding for the tyrosine kinase KIT. The most common mutations are found in exon 11, followed by mutations in exon 9. The latter mutations are associated more frequently with GISTs in extra-gastric locations and with a more aggressive clinical behaviour.
Summary. Here, we review the unique and often poorly recognised molecular, biological and clinical characteristics that differentiate KIT exon 9-mutant GISTs from other GIST subtypes. In particular, KIT exon 9 mutations are associated to KIT mutants with retained...
Source: Chemotherapy - January 4, 2022 Category: Cancer & Oncology Source Type: research
Sarcopenia in Hepatocellular Carcinoma: Pathogenesis and Management
Background: Sarcopenia is almost constantly observed in patients with cirrhosis and hepatocellular carcinoma.
Summary: Chronic liver disease represents a unique pathophysiological scenario in which sarcopenia develops and all factors involved in the pathogenesis should be taken into account for an appropriate management of the disease. No properly designed intervention studies on this topic are available and, thus, no effective strategies have been developed for clinical practice. Apart from any targeted intervention, treatment and optimization of liver disease is crucial.
Key Messages: In patients with cirrhosis and h...
Source: Chemotherapy - December 31, 2021 Category: Cancer & Oncology Source Type: research
Crizotinib versus Alectinib for the Treatment of ALK-Positive Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
Background: Crizotinib and alectinib are the two most commonly used anaplastic lymphoma kinase (ALK) inhibitors for ALK-positive non-small cell lung cancer (NSCLC). We compared their antitumor efficacies and adverse effects based on a pooled analysis of the ALEX, ALESIA and J-ALEX clinical trials.
Methods: Seven databases were searched for eligible articles. The primary endpoints included overall survival (OS), progression-free survival (PFS), central nervous system (CNS)-PFS, drug responses and adverse effects (AEs).
Results: Seven articles on three randomized controlled clinical trials (ALEX, ALESIA and J-ALEX) that in...
Source: Chemotherapy - December 14, 2021 Category: Cancer & Oncology Source Type: research
Being a Cancer Patient during the Time of COVID-19: Impact of the Pandemic on the Anxiety and the Sleeping Quality of Oncology Patients
Conclusion: Anxiety and sleep quality levels were found comparable to pre-pandemic reports, and the pandemic was not observed to have additional negative impact on cancer patients. Also, universal basal anxiety and sleep disorder that accompany cancer or active treatment were observed in our study. The accurate effects of the pandemic can be analyzed in further studies using repeated data obtained from the same patient group.Chemotherapy (Source: Chemotherapy)
Source: Chemotherapy - December 7, 2021 Category: Cancer & Oncology Source Type: research
Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia: A Serologic and Cellular Study
This study was undertaken to assess humoral immune and cellular responses to the BNT162b2 messenger RNA (mRNA) COVID-19 vaccination in CLL.
Methods: The presence of the spike antibodies was assessed at a median time of 14 days from the second vaccine dose of SARS-CoV2 in 70 CLL followed-up at a single institution.
Results: The antibody response rate (RR) in CLL patients was 58.5%, compared to 100%
of 57 healthy controls of the same sex and age (P (Source: Chemotherapy)
Source: Chemotherapy - December 6, 2021 Category: Cancer & Oncology Source Type: research
Molecular Characterization, Virulence Determinants, and Antimicrobial Resistance Profile of Methicillin-Resistant < b > < i > Staphylococcus aureus < /i > < /b > in the North of Iran; a High Prevalence of ST239-SCC < b > < i > mec < /i > < /b > III/t037 Clone
Conclusion: These findings emphasize the need for future and continuous surveillance studies on MRSA to prevent the dissemination of existing multidrug resistance MRSA clones in an effective manner.Chemotherapy (Source: Chemotherapy)
Source: Chemotherapy - December 6, 2021 Category: Cancer & Oncology Source Type: research
Contents, Vol. 66, 2021
Chemotherapy 2021;66:I –IV (Source: Chemotherapy)
Source: Chemotherapy - December 2, 2021 Category: Cancer & Oncology Source Type: research
Acknowledgement to Reviewers
Chemotherapy 2021;66:210 (Source: Chemotherapy)
Source: Chemotherapy - December 2, 2021 Category: Cancer & Oncology Source Type: research
Dysregulated MDR1 by PRDM1/Blimp1 Is Involved in the Doxorubicin Resistance of Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma
Conclusion: In non-GCB DLBCL cells, NF- κB downregulates PRDM1 and thereby promotesMDR1 transcription by terminating PRDM1-induced transcriptional inhibition ofMDR1. Such a mechanism may explain the reason for disease recurrence in non-GCB DLBCL after R-CHOP or combined CHOP with bortezomib treatment. Our findings may provide a potential therapeutic strategy for reducing drug resistance in patients with DLBCL.Chemotherapy (Source: Chemotherapy)
Source: Chemotherapy - November 29, 2021 Category: Cancer & Oncology Source Type: research
Relationship between Carnitine Deficiency and Tyrosine Kinase Inhibitor Use in Patients with Chronic Myeloid Leukemia
Conclusion: Carnitine deficiency is probably not a major cause of general fatigue, but may occur in patients with CML receiving TKIs. (Source: Chemotherapy)
Source: Chemotherapy - November 26, 2021 Category: Cancer & Oncology Source Type: research
Synthesis and Antimicrobial Evaluation of Amino Acid Naphthoquinone Derivatives as Potential Antibacterial Agents
Conclusion: amino acid 1,4-naphthoquinone derivatives showed good in vitro antibacterial activity against clinical strains, and modifications on C-3 with cloride atom enhanced the efficiency against same pathogens. (Source: Chemotherapy)
Source: Chemotherapy - November 26, 2021 Category: Cancer & Oncology Source Type: research
Prolongation of Neoadjuvant Chemotherapy before Surgery: Seeking the Optimal Number of Cycles in Serous Ovarian Cancer
Conclusions: Patients with advanced-stage serous EOC who received more than 3 cycles of NACT had poor OS. However, there was no statistical difference in terms of DFS. In addition, #x3e;3 cycles of NACT did not increase the probability of achieving complete cytoreduction at the time of surgery.Chemotherapy (Source: Chemotherapy)
Source: Chemotherapy - November 16, 2021 Category: Cancer & Oncology Source Type: research
The Pentose Phosphate Pathway in Cancer: Regulation and Therapeutic Opportunities
This article reviews the regulation of the PPP and discusses inhibitors that target its main pathways.Key Message: Exploiting the metabolic vulnerability of the PPP offers potential novel therapeutic opportunities and improves patients ’ response to cancer therapy.Chemotherapy (Source: Chemotherapy)
Source: Chemotherapy - November 12, 2021 Category: Cancer & Oncology Source Type: research
miR-142-3p Regulates Tumor Cell Autophagy and Promotes Colon Cancer Progression by Targeting TP53INP2
Conclusion: miR-142-3p hampered tumor cell autophagy and promoted CC progression via targeting TP53INP2, which will offer a fresh research orientation for the diagnosis of CC. (Source: Chemotherapy)
Source: Chemotherapy - November 9, 2021 Category: Cancer & Oncology Source Type: research
